04/28/2026
Not standard. Not settled. Still under the microscope.
Ivermectin is FDA-approved for certain parasitic infections, not cancer — but researchers are still testing whether it can disrupt tumor signaling, stemness, motility, and immune response. One metastasis-focused preclinical study in colorectal and breast models reported reduced cell motility in vitro and reduced tumor metastasis in vivo, including Wnt/β-catenin-related effects. A 2025 review said the broader oncology signal remains mostly preclinical.
Human data are still early. In metastatic triple-negative breast cancer, a phase I/II trial is recruiting, and a 2025 ASCO abstract reported the ivermectin + balstilimab combo was safe and well tolerated in a small heavily pretreated cohort, with one partial response and a 4-month clinical benefit rate of 37.5%. That is a signal for more study — not proof, not protocol, not standard of care.
At AN Scientific, we don’t chase miracle-cure language. We watch mechanisms, models, and early clinical reads — then wait for endpoints before making claims.
Disclaimer: For informational and educational purposes only. This content is not medical advice, diagnosis, treatment, or a recommendation to use ivermectin. Cancer treatment decisions should be made with a licensed oncology team.
-Link In Bio
